Table 14. INTERMACS 3rd Annual Meeting, March 2009, Orlando.
Intermacs: June 2006 –Sept 2008 Adult Prospective Implants | ||||
---|---|---|---|---|
Measurement | Pre-implant | Follow-up Visits* | ||
|
|
|||
n | % of 957* | n | % of 878 | |
Creatinine | 953 | 99.6% | 656 | 74.7% |
Bilirubin | 872 | 91.1% | 479 | 54.6% |
INR | 902 | 94.2% | 476 | 54.2% |
NYHA | 867 | 90.6% | 535 | 60.9% |
EuroQoL | 323 | 33.8% | 349 | 39.7% |
Trailmaking Test | 255 | 26.6% | 308 | 35.1% |
6 min walk | 30 | 3.1% | 133 | 15.1% |
VO2 Max | 58 | 6.1% | 25 | 2.8% |
The total possible follow-up visits at 3, 6 and 12 months is 878 among survivors.